Reply from the authors: Motor complications in Parkinson disease: Clinical manifestations and management

Journal of the Neurological Sciences

Volumn 273, Issue 1-2, 2008, Pages 156-157

  Bhidayasiri, Roongroj ^a,b,c   Truong, Daniel D ^c  

^a KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Parkinson's and Movement Disorder Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

AUTOPSY; DENERVATION; DISEASE DURATION; DISEASE SEVERITY; DRUG TOLERANCE; DYSKINESIA; HUMAN; LETTER; MOTOR DYSFUNCTION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

EID: 50049110256     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2008.06.018     Document Type: Letter

References (16)

1. Bhidayasiri R., and Truong D.D. Motor complications in Parkinson disease: clinical manifestations and management. J Neurol Sci 266 1-2 (2008) 204-215
2. Ahlskog J.E., and Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16 (2001) 448-458
3. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 47 4 Suppl 1 (2000) S2-9 [discussion S9-11.]
4. Gunzler S.A., and Nutt J.G. Motor fluctuations and dyskinesias. In: Factor S.A., and Weiner W.J. (Eds). Parkinson's disease: diagnosis and clinical management. 2nd ed (2007), Demos Medical Publishing 575-583
5. Schrag A., and Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease: a community-based study. Brain 123 (2000) 2297-2305
6. Fahn S., Oakes D., Shoulson I., et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 351 24 (2004) 2498-2508
7. Golbe L.I. Young-onset Parkinson's disease: a clinical review. Neurology 41 (1991) 168-173
8. Denny A.P., and Behari M. Motor fluctuations in Parkinson's disease. J Neurol Sci 165 1 (1999) 18-23
9. Nutt J.G., Carter J.H., Van Houten L., and Woodward W.R. Short- and long-duration responses to levodopa during the first year of levodopa therapy. Ann Neurol 42 3 (1997) 349-355
10. Chase T.N. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology 50 5 Suppl 5 (1998) S17-25
11. Nutt J.G., and Holford N.H. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 39 5 (1996) 561-573
12. Calon F., Birdi S., Rajput A.H., Hornykiewicz O., Bedard P.J., and Di Paolo T. Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias. J Neuropathol Exp Neurol 61 2 (2002) 186-196
13. Nutt J.G., Woodward W.R., Carter J.H., and Gancher S.T. Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon. Arch Neurol 49 11 (1992) 1123-1130
14. Nutt J.G., and Woodward W.R. Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology 36 6 (1986) 739-744
15. Metman L.V., van den Munckhof P., Klaassen A.A., Blanchet P., Mouradian M.M., and Chase T.N. Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson's disease. Neurology 49 3 (1997) 711-713
16. Nutt J.G. Continuous dopaminergic stimulation: is it the answer to the motor complications of Levodopa?. Mov Disord 22 1 (2007) 1-9